Immatics N.V. (NASDAQ:IMTX) Is a Favorite Amongst Institutional Investors Who Own 50%
Perceptive Advisors LLC Reduces Stake in Immatics NV
6-K: Report of foreign private issuer (related to financial reporting)
Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
More Unpleasant Surprises Could Be In Store For Immatics N.V.'s (NASDAQ:IMTX) Shares After Tumbling 26%
Express News | Immatics NV : Leerink Partners Cuts Target Price to $19 From $21
Exchange-Traded Funds Down, Equity Futures Mixed Pre-Bell Friday as Investors Gear Up for Earnings Season
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
Immatics Down Over 11%, On Track for Largest Percent Decrease Since September 2022 -- Data Talk
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Immatics to Raise $150M via Public Offering>IMTX
Immatics Announces Proposed $150 Million Public Offering
Immatics Filed For Mixed Shelf Offering; Size Not Disclosed
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Immatics Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $19
Immatics' Promising Pipeline and Buy Recommendation: A Comprehensive Analysis by Joseph Catanzaro
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans